**Supplemental Table 1**

**A- Individual CSF Concentrations (Absolute Values) of p217+tau (total, bound and free) following multiple doses of 15 mg/kg JNJ-63733657 administered intravenously on Day 1, Day 29 and Day 57** **in participants with prodromal or mild AD.**

Bound is calculated as the difference between total and free p217+tau.

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  |  **CSF concentrations of p217+tau (total) (pmol/L)** |
| **Subject** | **Screening** | **Day 8** | **Day 15** | **Day 64** | **Day 71** | **Day 85** | **Day 148** |
| 1a | 2.0104 | 0.6196 | - | 1.0247 | - | 1.2245 | - |
| 2b | 4.8471 | - | 1.0207 | - | 0.9415 | - | 2.2415 |
| 3a | 1.3807 | 0.398 | - | 0.4099 | - | 0.4405 | - |
| 4a | 9.6624 | 2.8901 | - | 1.4753 | - | 1.79 | - |
| 5b | 9.1568 | - | 2.1653 | - | 1.8444 | - | 3.2878 |
| 6b | 3.5872 | - | 0.9227 | - | 0.8791 | - | NS |
| **Subject** | **CSF concentrations of p217+tau (free) (pmol/L)** |
| **Screening** | **Day 8** | **Day 15** | **Day 64** | **Day 71** | **Day 85** | **Day 148** |
| 1a | 2.1179 | 0.2921 | - | 0.3159 | - | 0.5806 | - |
| 2b | 4.8192 | - | 0.6061 | - | 0.4589 | - | 1.7691 |
| 3a | 1.4601 | 0.1627 | - | 0.1395 | - | 0.2004 | - |
| 4a | 10.1193 | 1.5767 | - | 0.6609 | - | 1.1123 | - |
| 5b | 10.5903 | - | 1.104 | - | 0.8573 | - | 2.5095 |
| 6b | 4.0731 | - | 0.568 | - | 0.4447 | - | NS |
| **Subject** | **CSF concentrations of p217+tau (bound) (pmol/L)** |
| **Screening** | **Day 8** | **Day 15** | **Day 64** | **Day 71** | **Day 85** | **Day 148** |
| 1a | 0 | 0.328 | - | 0.709 | - | 0.644 | - |
| 2b | 0.0279 | - | 0.415 | - | 0.483 | - | 0.472 |
| 3a | 0 | 0.235 | - | 0.270 | - | 0.240 | - |
| 4a | 0 | 1.31 | - | 0.814 | - | 0.678 | - |
| 5b | 0 | - | 1.06 | - | 0.987 | - | 0.778 |
| 6b | 0 | - | 0.355 | - | 0.434 | - | NS |

-: Timepoint not included in CSF sampling scheme.

NS: No Sample.

a Subject randomized to CSF sampling scheme 1: Baseline, Day 8, Day 64 and Day 85.

b Subject randomized to CSF sampling scheme 2: Baseline, Day 15, Day 71 and Day 148.

 **B. Individual CSF Concentrations (Absolute Values) of p217+tau (total, bound and free) following multiple doses of 30 mg/kg JNJ-63733657 administered intravenously on Day 1, Day 29 and Day 57 in participants with prodromal or mild AD.**

Bound is calculated as the difference between total and free p217+tau.

|  |  |
| --- | --- |
|  **Subject** | **CSF concentrations of p217+tau (total) (pmol/L)** |
| **Screening** | **Day 8** | **Day 15** | **Day 64** | **Day 71** | **Day 85** | **Day 148** |
| 7c | 14.5168 | NS | NS | NS | NS | NS | NS |
| 8b | 8.2609 | - | 2.0124 | - | 2.1062 | - | 2.8219 |
| 9a | 11.0875 | 2.3983 | - | 1.5265 | - | 1.7692 | - |
| 10b | 5.563 | - | 0.8815 | - | 0.5489 | - | 1.1235 |
| 11a | 8.7482 | 1.752 | - | 1.5322 | - | 1.8448 | - |
| **Subject** | **CSF concentrations of p217+tau (free) (pmol/L)** |
| **Screening** | **Day 8** | **Day 15** | **Day 64** | **Day 71** | **Day 85** | **Day 148** |
| 7c | 14.4497 | NS | NS | NS | NS | NS | NS |
| 8b | 7.001 | - | 0.7049 | - | 0.5336 | - | 1.9291 |
| 9a | 11.8096 | 0.9147 | - | 0.4785 | - | 0.6516 | - |
| 10b | 6.1407 | - | 0.3378 | - | 0.1562 | - | 0.6824 |
| 11a | 8.1192 | 0.6574 | - | 0.5322 | - | 0.9751 | - |
| **Subject** | **CSF concentrations of p217+tau (bound) (pmol/L)** |
| **Screening** | **Day 8** | **Day 15** | **Day 64** | **Day 71** | **Day 85** | **Day 148** |
| 7c | 0.0671 | NS | NS | NS | NS | NS | NS |
| 8b | 1.26 | - | 1.31 | - | 1.57 | - | 0.893 |
| 9a | 0 | 1.48 | - | 1.05 | - | 1.12 | - |
| 10b | 0 | - | 0.544 | - | 0.393 | - | 0.441 |
| 11a | 0.629 | 1.09 | - | 1.00 | - | 0.870 | - |

-: Timepoint not included in CSF sampling scheme.

NS: No Sample.

a Subject randomized to CSF sampling scheme 1: Baseline, Day 8, Day 64 and Day 85.

b Subject randomized to CSF sampling scheme 2: Baseline, Day 15, Day 71 and Day 148.

c CSF sampling scheme unknown due to multiple missing samples.